Cover Image
QR Code

Risk Factors for Febrile Neutropenia in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Undergoing Initial R-CHOP Treatment.

Background: Febrile neutropenia (FN) frequently occurs as a complication among patients with diffuse large B-cell lymphoma (DLBCL) receiving their initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. This study aimed to identify the risk factors for FN...

Full description

Published in:Clinical Medicine Insights: Oncology Vol. 20; pp. 1 - 9
Main Authors: Chen, Liang-Ying, Tsai, Che-An, Liao, Po-Wei, Teng, Ling-Chiao, Lin, Cheng-Hsien, Su, Yu-Chen, Teng, Chieh-Lin Jerry
Format: research tables/charts Journal Article
Published: Sage Publications Inc. 2/18/2026
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191764140&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 191764140
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11795549
        B3KT
      jtl: Clinical Medicine Insights: Oncology
      issn: 11795549
      maglogo: Y
    pubinfo:
      dt: 2/18/2026
      vid: 20
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        191764140
        191764140
        191764140
        10.1177/11795549261423995
        191764140
      ppf: 1
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Risk Factors for Febrile Neutropenia in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Undergoing Initial R-CHOP Treatment.
      aug:
        au:
          Chen, Liang-Ying
          Tsai, Che-An
          Liao, Po-Wei
          Teng, Ling-Chiao
          Lin, Cheng-Hsien
          Su, Yu-Chen
          Teng, Chieh-Lin Jerry
        affil: Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung
      sug:
        subj:
          Lymphoma, B-Cell Complications
          Febrile Neutropenia Risk Factors
          Lymphoma, B-Cell Drug Therapy
          Antineoplastic Agents, Combined Therapeutic Use
          Prediction Models
          Risk Assessment
          Machine Learning
          Funding Source
          Human
          Male
          Female
          Middle Age
          Aged
          Descriptive Statistics
          Retrospective Design
          Record Review
          Odds Ratio
          Confidence Intervals
          Logistic Regression
          Scales
          Lactate Dehydrogenase Analysis
          Overall Survival
          Univariate Statistics
          Multivariate Analysis
          Prospective Studies
          Chi Square Test
          Mann-Whitney U Test
          Fisher's Exact Test
          Kaplan-Meier Estimator
          Log-Rank Test
          Cox Proportional Hazards Model
          Data Analysis Software
          Prostate-Specific Antigen
          Plants, Medicinal
          Artificial Intelligence
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Background: Febrile neutropenia (FN) frequently occurs as a complication among patients with diffuse large B-cell lymphoma (DLBCL) receiving their initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. This study aimed to identify the risk factors for FN and create a reliable predictive model for FN using machine learning methods. Methods: This retrospective study evaluated 238 patients newly diagnosed with DLBCL and treated with the R-CHOP regimen. Logistic regression was used to identify the risk factors for FN. In addition, a machine learning model was developed to predict the occurrence of FN. Results: The incidence rate of FN was 23.9%. Univariate analysis revealed significant associations between FN and bone marrow involvement (odds ratio [OR], 2.78; 95% confidence interval [CI], 1.36-5.66; P =.005), stage III and IV disease (OR, 3.39; 95% CI, 1.69-6.84; P =.001), Eastern Cooperative Oncology Group Performance Status score of ⩾ 2 (OR, 2.75; 95% CI, 1.13-6.67; P =.025), lactate dehydrogenase levels ⩾ 240 U/L (OR, 2.68; 95% CI, 1.35-5.32; P =.005), and involvement of at least 2 extranodal sites (OR, 2.69; 95% CI, 1.44-5.02; P =.002). Machine learning techniques were applied to construct predictive models for FN, achieving C-statistics of 0.751 to 0.879 in cross-validation and 0.692 to 0.861 in independent training and testing experiments. Notably, patients with FN (57.6%) had a substantially inferior 5-year overall survival (OS) rate than those without FN (77.1%) (P =.007). Conclusions: Patients with DLBCL who develop FN after their first R-CHOP treatment have a significantly worse OS than those without FN. Tailored prophylaxis with granulocyte-colony stimulating factor and antibiotics may be essential in this population. Models with moderate to strong predictive power can be designed using various artificial intelligence techniques.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N